All In Biotech

Drug Trial Radar · NCT03559257

A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study

Last checked: Nov 20, 2026Latest source record: Jul 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 463 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

463

Actual

Start

Jul 31, 2018

Primary completion

Jun 19, 2019

Study completion Sep 19, 2019

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jun 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.

Conditions

  • Migraine

Interventions

  • GalcanezumabDrug

    Administered SC.

  • PlaceboDrug

    Administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Mean Change From Baseline in the Number of Monthly Migraine Headache DaysTime frame: Baseline, Month 1 through Month 3

Locations

69 sites in 13 countries. Site status is shown where the registry gives one.

  • 21st Century Neurology

    Phoenix, Arizona

  • Medical Center for Clinical Research

    San Diego, California

  • Sensible Healthcare

    Ocoee, Florida

  • University of South Florida

    Tampa, Florida

  • Renstar Medical Research

    Wesley Chapel, Florida

  • Boston Clinical Trials

    Boston, Massachusetts

  • Michigan Head, Pain and Neurological Institute

    Ann Arbor, Michigan

  • Clinical Research Institute

    Minneapolis, Minnesota

  • Healthy Perspectives Innovative Mental Health Services, PL

    Nashua, New Hampshire

  • Bio Behavioral Health

    Toms River, New Jersey

  • Albuquerque Clinical Trials

    Albuquerque, New Mexico

  • Rochester Clinical Research, Inc.

    Rochester, New York

  • PharmQuest

    Greensboro, North Carolina

  • Lehigh Center for Clinical Research

    Allentown, Pennsylvania

  • Coastal Carolina Research Center, Inc.

    Mt. Pleasant, South Carolina

  • Foothill Family Clinic

    Salt Lake City, Utah

  • Health Research of Hampton Roads Inc

    Newport News, Virginia

  • Northwest Clinical Research Center

    Bellevue, Washington

  • Algemeen Ziekenhuis St Jan Brugge

    Bruges, Belgium

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Okanagan Clinical Trials

    Kelowna, British Columbia, Canada

  • Aggarwal and Associates Ltd

    Brampton, Ontario, Canada

  • DIEX Recherche Sherbrooke, Inc

    Sherbrooke, Quebec, Canada

  • Neurologicka ambulance, Neurologie Brno s.r.o.

    Brno, Czechia

  • Brain-Soultherapy s.r.o

    Kladno, Czechia

  • DADO MEDICAL, s.r.o.

    Prague, Czechia

  • Neurologicka ordinace

    Prague, Czechia

  • Institut Neuropsychiatricke Pece

    Prague, Czechia

  • Clintrial, s.r.o.

    Prague, Hl. M. Praha, Czechia

  • Hôpital de Cimiez

    Nice, France

  • CHU St Etienne Hopital Nord

    Saint-Etienne, France

  • CHRU de Lille- Hôpital Roger Salengro

    Lille, Cedex, France

  • Charité Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • DRK-Kliniken Nordhessen

    Kassel, Hesse, Germany

  • Praxis Dr. Philipp Stude

    Bochum, North Rhine-Westphalia, Germany

  • Universitätsklinikum Jena

    Jena, Thuringia, Germany

  • SE Neurologiai Klinika

    Budapest, Hungary

  • Orszagos Idegtudomanyi Intezet

    Budapest, Hungary

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.